Caribou Biosciences
CRBU
131 hedge funds and large institutions have $273M invested in Caribou Biosciences in 2022 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 36 increasing their positions, 38 reducing their positions, and 10 closing their positions.
864% more call options, than puts
Call options by funds: $588K | Put options by funds: $61K
180% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 10
16% more funds holding
Funds holding: 113 → 131 (+18)
0.2% more ownership
Funds ownership: 71.06% → 71.26% (+0.2%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 38
40% less capital invested
Capital invested by funds: $457M → $273M (-$184M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$14.8M |
| 2 |
RCMU
Rokos Capital Management (UK)
London,
United Kingdom
|
+$7.48M |
| 3 |
State Street
Boston,
Massachusetts
|
+$7.15M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.58M |
| 5 |
BlackRock
New York
|
+$2.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$13.7M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$9.46M |
| 3 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$6.56M |
| 4 |
DFO
Duquesne Family Office
New York
|
-$2.86M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$2.61M |
CRBU Hedge Fund Activity: Q4 2022 in Review
131 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q4 2022, worth a combined $273M — down 40% from $457M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CRBU positions and 10 closed out — a net gain of 18 holders — while 36 added to existing stakes and 38 trimmed.
The largest buyer was Bank of America, adding an estimated $14.8M. The largest seller was PFM Health Sciences, cutting an estimated $13.7M.
- 131 institutional investors held Caribou Biosciences (CRBU) as of Q4 2022, up from 113 in Q3 2022.
- Funds reported $273M of Caribou Biosciences stock for Q4 2022, down 40% quarter-over-quarter.
- 28 funds opened new Caribou Biosciences positions in Q4 2022 and 10 closed out, a net change of +18 holders.
- The largest Caribou Biosciences buyer in Q4 2022 was Bank of America, an estimated $14.8M added.
- The largest Caribou Biosciences seller in Q4 2022 was PFM Health Sciences, an estimated $13.7M sold.
Based on aggregated 13F filings for Q4 2022.